

Aubagne, July 22, 2025

Information on Document Availability

The report on the first half 2025 results of Sartorius Stedim Biotech Group (Paris: DIM) is now available at: <https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biotech-sa-investor-relations>

It contains the following information:

- Business development for the period of January to June 2025 as well as the 2025 full year forecast for the Sartorius Stedim Biotech Group
- Consolidated financial statements for the period ended June 30, 2025

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner to the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, more safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are listed on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2024, the company generated sales revenue of around 2.8 billion euros. More than 9,900 employees work for customers around the globe.

Contact

Petra Müller
Head of Investor Relations
+49 (0)551.308.6035
petra.mueller2@sartorius.com